Kura Oncology, Inc. Common Stock

Kura Oncology, Inc. operates as a clinical-stage biopharmaceutical company, which engages in the research and development of medicines for the treatment of cancer. The company is headquartered in San Diego, California and currently employs 260 full-time employees. The company went IPO on 2015-11-05. The firm is focused on precision medicine for the treatment of cancer. Its pipeline consists of small molecule product candidates that target cancer signaling pathways. Its product candidates include KOMZIFTI (Ziftomenib), Tipifarnib, and Darlifarnib (KO-2806). Ziftomenib, is a potent, selective, reversible and oral small molecule inhibitor that blocks the interaction of two proteins, menin and the protein expressed by the Lysine K-specific Methyl Transferase 2A gene, or KMT2A gene. Ziftomenib is a selective investigational inhibitor of the menin-KMT2A protein-protein interaction for the treatment of genetically defined subsets of acute leukemias. Tipifarnib is a potent, selective and orally bioavailable farnesyl transferase inhibitor (FTI). The KO-2806 is an FTI, is being evaluated in a Phase I first-in-human trial as a monotherapy and in combination with other targeted therapies.